Day One
Tuesday 10th June 2025
8:00 am Check In, Coffee & Light Breakfast
8:55 am Chair’s Opening Remarks
REVITALIZING THE PSYCHOSIS TREATMENT LANDSCAPE WITH NEW TARGETS & MECHANISMS: WHAT’S COMING NEXT IN 2025?
9:00 am The Evolution of Muscarinic Therapies : A New Era in Treating Schizophrenia and Other Neuropsychiatric Disorders
Synopsis
- The discovery of anti-psychotic drugs
- The history and mode of action of xanomeline in early Alzheimer’s studies
- Exploring the potential efficacy of mAChR agonists for treating all three core symptom domains of schizophrenia, and in other indications, such as: dementiaassociated psychosis, Alzheimer’s disease , Parkinson’s psychosis , bipolar disorder and more
9:30 am Reviewing the Journey of Cobenfy So Far & Future Directions for its Applications in Indications Beyond Schizophrenia
Synopsis
- Spotlighting the novel mechanism of action of Cobenfy and its selective muscarinic activation in the brain
- Demonstrating efficacy and safety in the ADEPT-2 Phase 3 Trial for Cobenfy in Alzheimer’s disease psychosis
- What are the opportunities for Cobenfy to be investigated for the treatment of psychosis in other dementias, bipolar, autism, and more?
10:00 am Panel Discussion: Advances in the Development of Muscarinic Agonists – Learnings from Clinical Trials, Addressing Biology & Subtype Selectivity
Synopsis
- What can we learn from the failure of Emraclidine? What can we decipher from post-mortem analyses? How much of a role did trial oversight and placebo responses influence the results of the EMPOWER trials?
- Understanding Subtype-Specific Functions. Is M1 and M4 receptor agonism necessary for efficacy?
OVERCOMING THE BOTTLENECKS OF CLINICALLY INVESTIGATING PSYCHOTIC POPULATIONS
11:30 am Putting out the Fire in the Brain: New Mechanisms, New Opportunities
Synopsis
- Anti-NMDA encephalitis is well known to cause acute psychosis
- 50% of patients presenting with new-onset schizophrenia and mania have high circulating titers of a previously unrecognized retrovirus
- Targeting this and other anti-NMDA infections has demonstrated efficacy in animals and early human trials
12:00 pm Innovation in Compliance: Earlier Initiation of Long-Acting Injectables to Avoid Relapse & Improve Patient Outcomes
Synopsis
- Leveraging long-acting injectables (LAIs) as an early intervention to address non-compliance in psychosis treatment, advanced delivery systems, and patient-centric solutions
- Highlighting the benefits of early LAI initiation, improved side-effect profiles
- To reduce relapses, prevent chronicity, and improve treatment outcomes by minimizing the biological and psychological impacts of non-compliance, fostering better patient experiences, and advancing long-term recovery
INNOVATING MORE OBJECTIVE & MEASURABLE BIOMARKERS OF PSYCHOSIS
2:00 pm Demonstrating the Potential of Digital Biomarkers to Overcome Heterogeneity & Select Specific Schizophrenic Subpopulations
Synopsis
- Introducing personalized treatment strategies in psychosis drug development by identifying patient subgroups based on digital biomarkers and clinical characteristics
- Reducing trial size and time by focusing on populations most likely to respond, enhancing drug efficacy, and minimizing adverse effects, especially in cases where traditional antipsychotics fail
2:30 pm Panel Discussion: Evaluating the Diversity of Biomarkers in Development for Psychosis: The Rationale Behind Biomarker Selection & Where They Fit into R&D for Psychosis Therapeutics
Synopsis
Audience Q&A with:
- Alto Neuroscience – Precision Psychiatry PlatformTM
- Monument Therapeutics – Digital Biomarker
3:00 pm Roundtable Discussion: Addressing the Unmet Needs of Negative & Cognitive Symptoms in Schizophrenia: What Opportunity is There to Digitally Treat Schizophrenia?
Synopsis
Practical and highly interactive breakout roundtables where attendees can crowd-source solutions and share opinions around pre-assigned topic areas:
- Addressing the lack of functional improvement in psychotic patients due to the unmet needs of negative and cognitive symptoms
- Combining therapies specifically aiming to restore motivation, social engagement, and independence
- Exploring transdiagnostic approaches for shared cognitive deficits across schizophrenia, Alzheimer’s, and other CNS disorders
Moderators will be assigned to each roundtable to facilitate discussion and collate the findings. Following the roundtable discussions, they will present back to the entire delegation and open a wider audience debate.
EXPLORING NEW OPPORTUNITIES TO TARGET PSYCHOSIS ACROSS THE DISEASE SPECTRUM
4:00 pm Roundtable Discussion: Benchmarking Opportunities, Risks & Challenges of Studying & Therapeutically Targeting Psychotic Symptoms in Dementia, Bipolar, PTSD, Depression, Autism, ADHD & More
Synopsis
Practical and highly interactive breakout roundtables where attendees can crowd-source solutions and share opinions around pre-assigned topic areas:
- Dementia-Associated Psychosis
- Bipolar & PTSD
- Severe Depression
- Autism & ADHD
Moderators will be assigned to each roundtable to facilitate discussion and collate the findings. Following the roundtable discussions, they will present back to the entire delegation and open a wider audience debate.
5:00 pm Chair’s Closing Remarks
5:05 pm Scientific Poster Session
Synopsis
This is an informal session to help you connect with your peers in a relaxed atmosphere to continue forging new and beneficial relationships. With an audience of preclinical, translational, and clinical scientists eager to hear the latest advancements in therapeutic development for psychosis, you will have the opportunity to display a poster presenting your work and innovations. Don’t miss out on the chance to connect, learn and present.